Neurocutaneous melanosis and negative fluorodeoxyglucose positron emission tomography by Leung, GKK et al.
Title Neurocutaneous melanosis and negative fluorodeoxyglucosepositron emission tomography
Author(s) Li, LF; Leung, SC; Chan, SK; Leung, GKK
Citation Surgical Practice, 2010, v. 14 n. 3, p. 107-110
Issued Date 2010
URL http://hdl.handle.net/10722/125440
Rights The definitive version is available at www.blackwell-synergy.com
Title page 
Title: Neurocutaneous melanosis and negative fluorodeoxyglucose positron emission 
tomography. 
 
Authors: Lai-fung LI, MRes(Med)1; Shue-cheong LEUNG, MRCS1; Siu-ki CHAN, 
MRCPath2, Gilberto Ka-kit LEUNG, FRCS1. 
 
Affiliation: 
1. Division of Neurosurgery, Department of Surgery, Li Ka Shing Faculty of Medicine, The 
University of Hong Kong 
2. Department of Pathology, Queen Mary Hospital, Hong Kong, People’s Republic of China 
 
Corresponding author: Lai-fung LI 
Mail address: Division of Neurosurgery, Department of Surgery, Li Ka Shing Faculty of 
Medicine, The University of Hong Kong 
Telephone: (852) 28553368 
Fax: (852) 28184350 
Email: llfrandom@gmail.com 
 
Reprint request: Lai-fung LI 
Mail address: Division of Neurosurgery, Department of Surgery, Li Ka Shing Faculty of 
Medicine, The University of Hong Kong 
Telephone: (852) 28553368 
Fax: (852) 28184350 
Email: llfrandom@gmail.com 
 Key words: neurocutaneous melanosis, PET, fluorodeoxyglucose 
 
Sources of Support: None 
 
Note: No portions of this work were presented previously. 
 
Abstract:  
Neurocutanous melanosis is a rare condition characterized by cutaneous melanocytic nevi 
and the presence of melanocyte in the leptomeninges. It is commonly associated with 
malignant melanoma formation in central nervous system (CNS) with poor prognosis. Here 
we report a 13-year old boy with neurocutaneous melanosis presented with seizure with 
diffuse CNS malignant melanoma as demonstrated by MRI. 18F-fluorodeoxyglucose positron 
emission tomography (PET) was performed but was unable to pick up the CNS involvement. 
So far, this is the first report involved the use of PET in neurocutaneous melanosis and we 
suggest MRI is more sensitive than PET with 18F-fluorodeoxyglucose in such condition. 
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Introduction 
Neurocutaneous melanosis (NCM) is a rare condition characterized by cutaneous giant 
melanocytic nevi and melanocyte in the leptomeninges. Diagnosis of NCM is made through 
both clinical findings of giant congenital naevus and radiological evidence of leptomeningeal 
melanosis. With the increasing use of positron emission tomography (PET), here we report 
the presentation of this condition together with the PET findings. 
 
History 
Our patient was a 13 year-old boy with good past health and family history of breast cancer. 
He presented in June of 2006 with 1-month history of headache followed by acute confusion 
and an episode of generalized tonic clonic seizure. Physical examination found a 10-cm sized 
hairy melanocytic naevus over right temporal-parietal region and right homonymous 
hemianopia. Plain computer tomography (CT) brain showed communicating hydrocephalus 
and a 1.4cm hyperdense lesion over the left medial temporal lobe without surrounding edema. 
Magnetic resonance imaging (MRI) showed the lesion was T1-hyperintense T2-isoinense 
with gadolinium contrast enhancement. There was no leptomeningeal enhancement. MRA 
and CTA were unremarkable. Blood tests and CSF exam were normal. Ventriculo-peritoneal 
shunting was performed for hydrocephalus. The family opted for conservative treatment for 
the lesion. 
 
MRI brain one month later showed increase in size of lesion with diffuse leptomeningeal 
enhancement. MRS showed increased choline peak and decreased N-acetylaspartic acid peak 
suggested a neoplastic process.  
 
Craniotomy and gross total resection of the tumour mass with biopsy of naevus were 
performed. The dura was dark-grey in colour. Histopathology revealed the tumour composed 
of epithelioid cells containing melanin with high nuclear/cytoplasm ratio, enlarged nuclei and 
prominent nucleoli. Diagnosis of malignant melanoma was made and confirmed by positive 
HMB45 and S-100 immunohistochemical staining. Proliferative marker (MIB1) confirmed 
high proliferation rate. Naevus biopsy showed congenital naevus with no evidence of 
malignancy. 
 
MRI of the spinal cord performed on post-operative day 17 showed diffuse enhancement with 
nodular thickening throughout the whole thecal sac that was compatible with diffuse CSF 
seedling. There was also encasement of cervical and proximal thoracic cord. Contrary, whole 
body PET with 18F-fluorodeoxyglucose(FDG) on the day after MRI exam could not show 
metastasis apart from post-operative changes (Fig. 1). 
 
Palliative chemotherapy with tamozolamide and radiotherapy were planned. Repeat CT brain 
showed new tumour deposit posterior to operative site with severe cerebral edema. His 
condition remained critical due to repeated seizure and finally passed away in August, 2006.  
 
Discussion 
Kadonaga and Frueden [1] defined NCM that includes 
 
1. Large (>20 cm largest adult diameter) or multiple (3 or more) congenital nevi in 
association with meningeal melanosis or melanoma. Infant lesion diameters of 9 cm on the 
head and 6 cm on the body are accepted because the projected growth of the lesion surface 
area is assumed to be proportional to normal skin growth of the body region it lies within. 
2. No evidence of cutaneous melanoma except when examined areas of meningeal lesions are 
histologically benign. 
3. No evidence of meningeal melanoma except when examined cutaneous lesions are 
histologically benign. 
 
The disease is not hereditary and affects both sexes equally without definite risk factor. Most 
patients presented at young age with hydrocephalus and seizure. Contrary, there are a few 
reported cases presented in adulthood up to age 65. Around 8-10% of NCM are associated 
with Dandy-Walker complex.  
 
Radiological diagnosis 
Diagnosis of NCM required both clinical and radiological findings that MRI plays an 
important role. Melanosis presents with T1 shortening with homogeneous gadolinium 
enhancement, and intermediate signal on T2-weighted images. However, variations had been 
reported with slightly hyperintense in T2-weighted images and hypointense on T1-weighted 
images for amelanotic melanoma. 
PET with FDG is effective in detection of extracranial malignant melanoma and superior to 
CT alone, while combining the two modalities, PET/CT was shown to be even more superior 
[2, 3]. Contrary, it had limitations in detecting brain metastasis, small lung nodules and 
lesions less than 10mm [4].  As a result, it is more useful for American Joint Committee on 
Cancer (AJCC) melanoma stage III and IV disease. One study comparing PET/CT with FDG 
and whole body MRI for advanced melanoma showed PET/CT had higher accuracy of 86.7% 
compared to that of MRI 78.8%, especially in terms of N-staging and detection of skin 
metastases, while MRI was more sensitive for liver, bone and brain metastasis [5]. Another 
study used both PET/CT and MRI for monitoring of progress of melanoma having 
chemotherapy treatment. Out of their 11 patients who had brain metastases, 9 of them were 
first picked up by MRI or contrast CT, only the rest of the two picked up by PET/CT. And 
the author emphasized that MRI should be used for detecting cerebral melanoma metastases 
for high risk patients [6]. Despite the relatively lower sensitivity for brain metastases, 
PET/CT was sensitive enough for extracranial disease monitoring that correlated well with 
clinical outcome after chemotherapy [6]. So far, there is no reported use of PET for NCM or 
melanosis. In our patient PET failed to demonstrate the diffuse CNS involvement that was 
shown by MRI. Despite NCM gives rise to melanoma, since the numbers of reported cases 
were limited, it is difficult to say if the behaviour of melanomas arising from NCM is same or 
different to those originated extracranially with cerebral metastases. Tumour characteristic is 
important in the current discussion as PET using FDG depends on the metabolic activities. 
Difference in terms of tumour nature, if exist, may affect the uptake of FDG and so the 
sensitivity of PET. Based on the result from cerebral metastases of melanoma and our current 
reported experience, MRI should be the first line imaging modality from diagnosis to 
subsequent treatment monitoring for NCM. But PET/CT may still play a role in excluding 
extracranial melanoma deposits as it is more sensitive to whole body MRI as extrancranial 
melanoma deposits almost exclude the diagnosis of NCM according to the definition. 
Despite there were a number of studies showing that PET with FDG was not very sensitive 
for cerebral metastasis of melanoma, there was no definite research or study addressing the 
reason behind. One of the purposed reason is that brain has high consumption of glucose and 
result in a strong background signal. High metabolic rate tissues like metastatic tumour, 
especially the small one, would be difficult to trace from this background [7]. The answer for 
this may be using isotopes more specific for tumour. 
 
Impact to current clinical practice 
Our patient developed diffuse leptomeningeal enhancement in MRI within 2 months and died 
within 3 months from presentation. It was suggested presence of giant congenital naevus 
should raise the suspicious of NCM and regular monitoring may be indicated. But the risk of 
having NCM and subsequent CNS melanoma was low upon 5 years follow up [8]. Moreover, 
this might not be feasible as leptomeningeal enhancement might occur at late stage with rapid 
progression. This implies early diagnosis of NCM is difficult. We suggest for patient with 
giant naevus, especially children as NCM mostly found in young patients, at least they should 
have regular clinical monitoring of the size of the naevus and new neurological symptoms.  
New abnormal behaviour or neurological deficits should raise the suspicious and urgent MRI 
brain is needed. They may also indicated for serial MRI brain but may be of low yield as 
mentioned previously, as well as for early biopsy for any subtle radiological change or 
development of definite nodule. 
The false negative of PET in our patient suggested monitoring of CNS disease progression 
should base on clinical features and MRI. But PET may be useful for detecting extracranial 
involvement as peritoneal seeding could occur if ventriculoperitoneal shunt was inserted [9]. 
Also it is worth to note that our observation on PET was based on FDG, employing other 
isotopes may be different. 
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Legends 
Figure 1. A, PET scan of brain and spinal cord without evidence of metastasis. B, 
T1-weighted image of whole spine. C, T1-weighted image with diffuse contrast 
enhancement and nodular thickening throughout whole thecal sac. 
